Ieq Capital LLC Has $359,000 Position in Allergan plc (NYSE:AGN)
Ieq Capital LLC lifted its stake in shares of Allergan plc (NYSE:AGN) by 91.0% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 2,027 shares of the company’s stock after acquiring an additional 966 shares during the period. Ieq Capital LLC’s holdings in Allergan were worth $359,000 at the end of the most recent reporting period.
Other institutional investors also recently added to or reduced their stakes in the company. Wealth Quarterback LLC acquired a new position in Allergan during the fourth quarter worth $25,000. Golden State Wealth Management LLC acquired a new position in Allergan during the first quarter worth $25,000. WASHINGTON TRUST Co acquired a new position in Allergan during the first quarter worth $25,000. Paragon Capital Management LLC acquired a new position in Allergan during the first quarter worth $30,000. Finally, Ellevest Inc. raised its holdings in Allergan by 233.3% during the first quarter. Ellevest Inc. now owns 180 shares of the company’s stock worth $32,000 after buying an additional 126 shares during the last quarter. Institutional investors own 83.91% of the company’s stock.
Several research analysts have weighed in on AGN shares. SunTrust Banks downgraded shares of Allergan from a “buy” rating to a “hold” rating and upped their price objective for the stock from $191.00 to $193.00 in a report on Tuesday, April 21st. Wells Fargo & Co downgraded shares of Allergan from an “overweight” rating to an “equal weight” rating and set a $198.00 price objective on the stock. in a report on Wednesday, January 22nd. Cfra downgraded shares of Allergan from a “buy” rating to a “hold” rating in a report on Wednesday, March 25th. Finally, ValuEngine upgraded shares of Allergan from a “sell” rating to a “hold” rating in a report on Tuesday, March 24th. Fourteen analysts have rated the stock with a hold rating and one has given a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $183.73.
The company also recently announced a quarterly dividend, which will be paid on Monday, June 15th. Stockholders of record on Thursday, April 16th will be issued a $0.74 dividend. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $2.96 annualized dividend and a dividend yield of 1.53%. Allergan’s dividend payout ratio is currently 16.78%.
Allergan Company Profile
Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products.
Recommended Story: Diluted Earnings Per Share
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.